Compare Aurora Cannabis Inc (ACB) vs GoPro Inc (GPRO) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

GoPro (GPRO) trades at $0.73, down 0.38% on the day, reflecting persistent financial distress. The stock is in a bearish technical trend, with negative earnings surprises in recent quarters and a net income margin of -20.7% for 2025. Revenue has declined from $1.1B in 2022 to $652M in 2025, while the company is actively pursuing strategic alternatives, including a potential sale, as announced in May 2026.

The outlook is highly speculative, hinging on the outcome of the strategic review. A successful sale could unlock value, but fundamental weaknesses—including cash burn, negative equity, and competitive pressures—pose significant risks. Analyst sentiment is mixed, with a majority Hold rating, indicating caution amid the binary event-driven thesis.